Recruitment for Remote Decentralized Studies in Parkinson's Disease

J Parkinsons Dis. 2022;12(1):371-380. doi: 10.3233/JPD-212935.

Abstract

Background: Traditional in-person Parkinson's disease (PD) research studies are often slow to recruit and place unnecessary burden on participants. The ongoing COVID-19 pandemic has added new impetus to the development of new research models.

Objective: To compare recruitment processes and outcomes of three remote decentralized observational PD studies with video visits.

Methods: We examined the number of participants recruited, speed of recruitment, geographic distribution of participants, and strategies used to enhance recruitment in FIVE, a cross-sectional study of Fox Insight participants with and without PD (n = 203); VALOR-PD, a longitudinal study of 23andMe, Inc. research participants carrying the LRRK2 G2019S variant with and without PD (n = 277); and AT-HOME PD, a longitudinal study of former phase III clinical trial participants with PD (n = 226).

Results: Across the three studies, 706 participants from 45 U.S. states and Canada enrolled at a mean per study rate of 4.9 participants per week over an average of 51 weeks. The cohorts were demographically homogenous with regard to race (over 95%white) and level of education (over 90%with more than a high school education). The number of participants living in primary care Health Professional Shortage Areas in each study ranged from 30.3-42.9%. Participants reported interest in future observational (98.5-99.6%) and interventional (76.1-87.6%) research studies with remote video visits.

Conclusion: Recruitment of large, geographically dispersed remote cohorts from a single location is feasible. Interest in participation in future remote decentralized PD studies is high. More work is needed to identify best practices for recruitment, particularly of diverse participants.

Keywords: Parkinson’s disease; decentralized; recruitment; telemedicine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • COVID-19
  • Cross-Sectional Studies
  • Humans
  • Longitudinal Studies
  • Pandemics
  • Parkinson Disease* / therapy
  • Patient Selection*